Andere talen Aclarion, Inc.

Aandelen

ACON

US6551872012

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 26-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,3084 ^USD	+6,34%		+4,54%	-90,36%

25/06	Aclarion breidt commerciële samenwerking met de London Clinic uit om de toegang tot Nociscan in Groot-Londen te vergroten	CI
15/05	Aclarion, Inc. Rapporteert winstresultaten voor het eerste kwartaal eindigend op 31 maart 2024	CI

Andere talen

Krijg toegang tot al het nieuws: wees als eerste op de hoogte en reageer voordat de beurs dat doet!

Gratis inschrijven

Aclarion : AXA is the 2nd largest provider of private medical insurance in the UK. Payer coverage is the most important catalyst Aclarion can achieve to drive volume and revenue. AXA represents the first insurance company to approve payment for Nociscan Form 8 K	26/06
Aclarion Announces Initial Payer Coverage of Nociscan by AXA Throughout Greater London, UK	26/06
Aclarion Expands Commercial Engagement With The London Clinic to Grow Access to Nociscan Throughout Greater London	25/06
Aclarion Expands Commercial Engagement with the London Clinic to Grow Access to Nociscan Throughout Greater London	25/06
Aclarion Receives Notice of Allowance for US Patent to Support Further Optimization of Accuracy and Reliability in the Nociscan Solution	20/06
Aclarion : Certificate of Incorporation/Bylaws Form 8 K	19/06
Aclarion Announces Updated Product Release That Enhances User-Experience, Scalability, and Security for Nociscan Solution	18/06
Certain Warrants of Aclarion, Inc. are subject to a Lock-Up Agreement Ending on 26-MAY-2024.	26/05
Certain Stock Options of Aclarion, Inc. are subject to a Lock-Up Agreement Ending on 26-MAY-2024.	26/05
Certain Common Stock of Aclarion, Inc. are subject to a Lock-Up Agreement Ending on 26-MAY-2024.	26/05
Aclarion, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05
Aclarion’s Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain	25/04
Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs	04/03
Aclarion Announces Closing of $3.0 Million Public Offering	27/02
Top Midday Decliners	26/02
Aclarion Announces Pricing of $3.0 Million Public Offering	26/02
Aclarion, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/02
Aclarion Announces Successful Financings; Plans to Launch CLARITY Trial and Provides Update on Next Steps of Alphatec Strategic Partnership	05/02
Top Premarket Decliners	02/02
Wall Street Set to Open Marginally Lower Friday; December Inflation Data Lower Than Forecast	26/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Aclarion, Inc.

Aandelen

ACON

US6551872012

Andere talen

Filters